The study demonstrated that a DL approach based on multisequence MRI can help to predict the EGFR mutation subtypes in NSCLC patients with BM, with potential beneficial effects to guide a personalized treatment. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.